Takayanagui O M, Jardim E
Department of Neurology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Arch Neurol. 1992 Mar;49(3):290-4. doi: 10.1001/archneur.1992.00530270106026.
Praziquantel and albendazole have been recently described as effective drugs for treatment of intraparenchymal brain cysticercosis. We performed a prospective study comparing the efficacy of these drugs. Twenty-two patients were treated with praziquantel and 21 with albendazole. In addition, 16 patients were treated with symptomatic drugs only and used as controls. Treatment was discontinued in two patients receiving praziquantel and one patient receiving albendazole owing to acute decompensation of the increased intracranial pressure, and one of them died. Albendazole and praziquantel were effective when compared with the control group. However, albendazole was significantly more effective than praziquantel in reducing the total number of cysts in the computed tomographic scans (88% vs 50%). Despite these results, however, analysis of clinical course showed a high frequency of neurologic sequelae. Considering the risks and fallibility of anticysticercal therapy, the real solution for this serious disease continues to be prophylaxis of infestation.
吡喹酮和阿苯达唑最近被描述为治疗脑实质内囊尾蚴病的有效药物。我们进行了一项前瞻性研究，比较了这些药物的疗效。22例患者接受吡喹酮治疗，21例接受阿苯达唑治疗。此外，16例患者仅接受对症药物治疗并作为对照组。接受吡喹酮治疗的2例患者和接受阿苯达唑治疗的1例患者因颅内压升高急性失代偿而停止治疗，其中1例死亡。与对照组相比，阿苯达唑和吡喹酮均有效。然而，在计算机断层扫描中，阿苯达唑在减少囊肿总数方面明显比吡喹酮更有效（88%对50%）。然而，尽管有这些结果，临床病程分析显示神经后遗症的发生率很高。考虑到抗囊尾蚴治疗的风险和易出错性，这种严重疾病的真正解决办法仍然是预防感染。
